These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 23671006

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
    Lebdai S, Basset V, Branchereau J, de La Taille A, Flamand V, Lebret T, Murez T, Neuzillet Y, Ploussard G, Audenet F.
    World J Urol; 2016 May; 34(5):617-24. PubMed ID: 26373956
    [Abstract] [Full Text] [Related]

  • 3. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [Abstract] [Full Text] [Related]

  • 4. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.
    Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, Agarwal N, Heath EI, Pal SK, Rehman HT, Leiter A, Batten JA, Montgomery RB, Galsky MD, Antonarakis ES, Chi KN, Yu EY.
    Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):122-7. PubMed ID: 25600186
    [Abstract] [Full Text] [Related]

  • 5. Pharmacotherapeutic strategies for castrate-resistant prostate cancer.
    Moussa M, Papatsoris A, Abou Chakra M, Sryropoulou D, Dellis A.
    Expert Opin Pharmacother; 2020 Aug; 21(12):1431-1448. PubMed ID: 32469248
    [Abstract] [Full Text] [Related]

  • 6. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
    Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, Dearnaley D, Parker C, de Bono JS, Attard G.
    Eur Urol; 2014 Sep; 66(3):459-65. PubMed ID: 24411987
    [Abstract] [Full Text] [Related]

  • 7. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
    Sternberg CN, Castellano D, de Bono J, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Poole EM, Ozatilgan A, Geffriaud-Ricouard C, de Wit R.
    Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
    [Abstract] [Full Text] [Related]

  • 9. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
    Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.
    Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
    [Abstract] [Full Text] [Related]

  • 10. Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
    Thiery-Vuillemin A, Poulsen MH, Lagneau E, Ploussard G, Birtle A, Dourthe LM, Beal-Ardisson D, Pintus E, Trepiakas R, Lefresne F, Lukac M, Van Sanden S, Pissart G, Reid A, AQUARiUS Investigators.
    Eur Urol; 2020 Mar; 77(3):380-387. PubMed ID: 31594705
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
    Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN.
    Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
    [Abstract] [Full Text] [Related]

  • 12. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
    Fizazi K, Kramer G, Eymard JC, Sternberg CN, de Bono J, Castellano D, Tombal B, Wülfing C, Liontos M, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Oudard S, Facchini G, Poole EM, Ozatilgan A, Geffriaud-Ricouard C, Bensfia S, de Wit R.
    Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
    [Abstract] [Full Text] [Related]

  • 13. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.
    Francini E, Yip S, Ahmed S, Li H, Ardolino L, Evan CP, Kaymakcalan M, Shaw GK, Kantoff PW, Taplin ME, Alimohamed NS, Joshua AM, Heng DYC, Sweeney CJ.
    Clin Genitourin Cancer; 2018 Apr; 16(2):130-134. PubMed ID: 29331381
    [Abstract] [Full Text] [Related]

  • 14. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
    de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Ozatilgan A, Geffriaud-Ricouard C, Castellano D, CARD Investigators.
    N Engl J Med; 2019 Dec 26; 381(26):2506-2518. PubMed ID: 31566937
    [Abstract] [Full Text] [Related]

  • 15. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
    de Bono JS, Chowdhury S, Feyerabend S, Elliott T, Grande E, Melhem-Bertrandt A, Baron B, Hirmand M, Werbrouck P, Fizazi K.
    Eur Urol; 2018 Jul 26; 74(1):37-45. PubMed ID: 28844372
    [Abstract] [Full Text] [Related]

  • 16. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
    van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM.
    Eur J Cancer; 2013 Dec 26; 49(18):3821-30. PubMed ID: 24200698
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis.
    Perletti G, Monti E, Marras E, Cleves A, Magri V, Trinchieri A, Rennie PS.
    Arch Ital Urol Androl; 2015 Jul 07; 87(2):121-9. PubMed ID: 26150028
    [Abstract] [Full Text] [Related]

  • 18. Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications?
    Arslan C.
    World J Urol; 2017 Mar 07; 35(3):479-480. PubMed ID: 27417948
    [No Abstract] [Full Text] [Related]

  • 19. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
    van Soest RJ, Nieuweboer AJ, de Morrée ES, Chitu D, Bergman AM, Goey SH, Bos MM, van der Meer N, Hamberg P, de Wit R, Mathijssen RH, Dutch Uro-Oncology Studygroup (DUOS).
    Eur J Cancer; 2015 Nov 07; 51(17):2562-9. PubMed ID: 26278646
    [Abstract] [Full Text] [Related]

  • 20. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.
    Thomsen FB, Røder MA, Rathenborg P, Brasso K, Borre M, Iversen P.
    Scand J Urol; 2014 Jun 07; 48(3):268-75. PubMed ID: 24255983
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.